Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B007 vs cyclosporine in primary membranous nephropathy
CTR20242028Phase 3Active
- Sponsor
- WuXi XDC
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of B007 in idiopathic membranous glomerulonephritis (IMG), sponsored by WuXi XDC. Started Jul 2024; status: active.
02
Drugs
B007
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20242028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242028.